|
|
|
Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) |
|
Biodexa Pharmaceuticals Plc
BDRX's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Biodexa Pharmaceuticals Plc's sales fell
by -45.49 % in the fourth quarter of 2023 from the same quarter a year ago.
Ranking at No. 3758
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
Biodexa Pharmaceuticals Plc net loss decreased from $-8 millions, to $-7 millions in fourth quarter of 2023,
• More on BDRX's Growth
|
|
Biodexa Pharmaceuticals Plc
reported net loss of -7 millions in the past twelve months.
|
| Company |
| |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.29.
• More on BDRX's Valuation
|
|
|
|
|
Biodexa Pharmaceuticals Plc
reported net loss of -7 millions in the past twelve months.
|
| Company |
| |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.29.
| | | |
